ONCE-DAILY

Adalat® LA

LONG ACTING

nifedipine 30mg & 60mg

FOR HYPERTENSION AND ANGINA

ADALAT LA30/ADALAT LA60 - ABRIDGED PRESCRIBING INFORMATION (Refer to full data sheet before prescribing) **Presentation:** Tablets each containing 30mg or 60mg nifedipine in a modified (extended) release formulation. **Indications:** Mild to moderate hypertension. Prophylaxis of angina pectoris either as monotherapy or in combination with a beta-blocker. **Dosage and Administration:** Adalat LA tablets must be swallowed whole; under no circumstances should they be bitten, chewed or broken up. One 30mg tablet once-daily swallowed whole with a glass of liquid to be taken at approximately 24-hour intervals, preferably during the morning. Dosage can be increased according to individual requirements up to a maximum of 90mg once-daily. Patients in whom hypertension or anginal symptoms are controlled on Adalat capsules or Adalat retard may be switched safely to Adalat LA. Prophylactic anti-anginal efficacy is maintained when patients are switched from other calcium antagonists such as diltiazem or verapamil to Adalat LA at the recommended initial dose of 30mg Adalat LA once-daily, with subsequent titration to a higher dose as warranted clinically. *Renal Impairment* Dosage adjustment should not be necessary. *Elderly* Dosage adjustment not usually necessary. Treatment may be continued indefinitely. *Children* No recommendations for use. **Contra-indications, warnings etc. Contra-indications:** Known hypersensitivity to nifedipine; severe aortic stenosis; cardiogenic shock; women of child-bearing potential and nursing mothers; hepatic impairment; history of gastro-intestinal obstruction, oesophageal obstruction, or any degree of decreased lumen diameter of the gastro-intestinal tract; inflammatory bowel disease or Crohn's disease. Concomitant administration with rifampicin. **Warnings and Precautions:** Outer membrane of tablet is not digested and may be seen in the toilet or associated with the patient's stools. If used in combination with beta-blocking drugs and other antihypertensives a possible additive effect resulting in postural hypotension should be borne in mind. Adalat LA will not prevent possible rebound effects after cessation of other anti-hypertensive therapy. Caution in patients with hypo-tension or whose cardiac reserve is poor. Deterioration of heart failure has occasionally been observed with nifedipine. If ischaemic pain is observed following the introduction of therapy, discontinue treatment. Diabetic patients may require adjustment of their control. Marked decrease in blood pressure can occur in dialysis patients with malignant hypertension and hypovolaemia. **Interactions:** Interactions have been observed withcimetidine, quinidine, digoxin, diltiazem and rifampicin. Spectrophotometric values of urinary vanillylmandelic acid may be increased falsely. **Side-effects:** Headache, flushing, tachycardia, palpitations, gravitational oedema, paraesthesia, dizziness, lethargy and gastro-intestinal symptoms such as nausea. Less commonly, skin reactions such as rash, pruritus and urticaria. Less frequently, myalgia, tremor, visual disturbances and increased frequency of micturition. Rare cases of gingival hyperplasia, gynaecomastia in older men on long-term therapy, hypersensitivity-type jaundice and disturbances of liver function such as intra-hepatic cholestasis, all of which regress on withdrawal of therapy. In isolated cases, photosensitivity, exfoliative dermatitis, systemic allergic reactions and purpura, which usually regress after discontinuation of the drug. **Legal Category:** POM. **Package Quantities and Basic NHS Costs:** Calendar packs containing 28 tablets; Adalat LA 30 £10.36, Adalat LA60 £15.40. **Product Licence Numbers:** PL 0010/0174-0175. **Date of Preparation:** March 1995.

Further information available from: Bayer plc, Pharmaceutical Division, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA. Telephone: (01635) 563000.

Bayer

WE LOOK FORWARD

TO SEEING YOU AT

THE BAYER STAND No 41